| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/19/2004 | WO2003032907A3 High-concentration protein formulations and method of manufacture |
| 02/19/2004 | WO2003014731A3 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/19/2004 | WO2002064160A3 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 02/19/2004 | WO2002048337A3 Secreted human proteins |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | WO2001020981A3 Anti-infective compositions for treating disordered tissue such as cold sores |
| 02/19/2004 | US20040034357 Controlled release implantable devices |
| 02/19/2004 | US20040034231 Amidinophenyl-4-aminoacetic acid derivative is useful for treating diseases such as thrombosis, apoplexy, cardiac infarction, inflammation and arteriosclerosis, which are associated with coagulation factors xa, IXa and thrombin |
| 02/19/2004 | US20040034218 Farnesyl transferase inhibiting benzoheterocyclic derivatives |
| 02/19/2004 | US20040034216 A gonane ring or with the nitrogen forming a heterocyclic structure; antiinflammation agents, antitumor agents; treating asthma, allergic disease, chronic obstructive pulmonary disease, atopic dermatitis, AIDS, arrhythmias |
| 02/19/2004 | US20040034104 2,2-Diphenylbutanamide derivatives and medicines containing the same |
| 02/19/2004 | US20040034090 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/19/2004 | US20040034086 For treatment of diseases characterized by connective tissue breakdown, cartilage damage, and inflammation/pain such as arthritis, heart failure, multiple sclerosis, atherosclerosis, and osteoporosis |
| 02/19/2004 | US20040034085 For treatment of cartilage damage, inflammation, arthritis, and pain; treating diseases such as rheumatoid arthritis/osteoarthritis, heart failure, multiple sclerosis, atherosclerosis, and osteoporosis |
| 02/19/2004 | US20040034082 Utilization of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of proliferative cell diseases |
| 02/19/2004 | US20040034073 Analgesic agents, modulating the activity of a cannabinoid receptor, treating hypertension, inflammation, pain, autoimmune diseases, allergic diseases, glaucoma, multiple sclerosis, Huntington's chorea, spinal chord injury |
| 02/19/2004 | US20040034072 Aza-amino acid derivatives (factor Xa inhibitors 15) |
| 02/19/2004 | US20040034062 Novel aqueous anti-inflammatory pharmaceutical formulation |
| 02/19/2004 | US20040034061 An antagonist of corticotropin releasing factor receptor, treating depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disorders, drug dependence |
| 02/19/2004 | US20040034059 A dosage concentration about 0.4 to 75 mg/mL of fentanyl in water, for the pain treatment |
| 02/19/2004 | US20040034058 Inhalation asthma treatment with an aqueous solution of (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl)carbonyl)oxy) phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy)acetyl)amino) pentanoyl)amino) propanoic acid or a salt |
| 02/19/2004 | US20040034054 Fused bicyclic metalloproteinase inhibitors |
| 02/19/2004 | US20040034052 Antitumor agents |
| 02/19/2004 | US20040034046 Quinazoline derivatives |
| 02/19/2004 | US20040034035 Calcium channel inhibitors comprising benzhydril spaced from piperazine |
| 02/19/2004 | US20040034034 Novel piperazine derivatives |
| 02/19/2004 | US20040034026 The use of a vasculostatic compound and a second active ingredient which decreases the activity of the epidermal growth factor (EGF); synergistic, angiogenesis inhibitors; antiproliferative agents; tyrosine kinase enzyme inhibitors |
| 02/19/2004 | US20040034020 A purine deriveative, useful for treatment of inflammatory conditions, immune disorders, tissue injury, infections, and cancer |
| 02/19/2004 | US20040034017 4-fluoroalkyl-2h-benzopyrans anti-estogenic activity |
| 02/19/2004 | US20040034009 1,6-Fused uracil derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | US20040033995 Nitrogen compounds, stereoisomers and/or racemic mixtures used as enzyme inhibitors for prophylaxis of inflammatory diseases |
| 02/19/2004 | US20040033994 Use of compounds comprising a nitrogen-oxygen heterocycle |
| 02/19/2004 | US20040033982 Viral inhibition by n-docosanol |
| 02/19/2004 | US20040033977 Oligonucleotide modulation of cell adhesion |
| 02/19/2004 | US20040033958 Such as (N-((R,S)-2-(2-(N-methyl)pyrrolidinyl)ethyl)glycyl)-(N-(4 -methoxyphenethyl)glycyl)-N-(3-methylbutyl)glycinamide; for treatment of pain |
| 02/19/2004 | US20040033933 Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof |
| 02/19/2004 | US20040033535 Antibodies to OPGL |
| 02/19/2004 | US20040033517 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (PAR1) |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033231 First domain comprising a PP14 polypeptide sequence and a second domain comprising a polypeptide sequence of the Fc region of an immunoglobulin protein; treatment of immune system diseases and disorders |
| 02/19/2004 | US20040033200 Modified FVII in treatment of ARDS |
| 02/19/2004 | DE10237423A1 Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
| 02/19/2004 | CA2497658A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2497656A1 Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495293A1 Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2495067A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494744A1 Use of fermented wheat germ extract as anti-inflammatory agent |
| 02/19/2004 | CA2494048A1 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2494028A1 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2494014A1 Monocyclic derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493008A1 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | CA2492112A1 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389616A1 Novel benzylpiperidine compound |
| 02/18/2004 | EP1389460A1 Cxcr4-antagonistic drugs comprising nitrogen-containing compound |
| 02/18/2004 | EP1389233A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389205A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 02/18/2004 | EP1389204A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| 02/18/2004 | EP1389200A1 Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors |
| 02/18/2004 | EP1389183A1 Sulfonamide derivatives |
| 02/18/2004 | EP1389181A2 Antioxidant nitroxides and nitrones as therapeutic agents |
| 02/18/2004 | EP1389180A1 Anti-inflammatory and immunomodulatory amino acid derivatives, their preparation and use |
| 02/18/2004 | EP1389131A2 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent |
| 02/18/2004 | EP1389129A1 Methods of treating respiratory conditions |
| 02/18/2004 | EP1389124A1 Palliative effects of morinda citrifolia oil and juice |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389108A2 Methods for selective immunomodulation using pimecrolimus |
| 02/18/2004 | EP1389107A1 Bisarylimidazolyl fatty acid amide hydrolase inhibitors |
| 02/18/2004 | EP1389103A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| 02/18/2004 | EP1389100A2 Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors |
| 02/18/2004 | EP1389099A1 Delivery of beta-blockers through an inhalation route |
| 02/18/2004 | EP1389098A1 Delivery of antipsychotics through an inhalation route |
| 02/18/2004 | EP1389097A1 Delivery of compounds for the treatment of parkinsons through an inhalation route |
| 02/18/2004 | EP1389096A1 Delivery of opioids through an inhalation route |
| 02/18/2004 | EP1389095A1 Delivery of antidepressants through an inhalation route |
| 02/18/2004 | EP1389094A1 Delivery of sedative-hypnotics trough an inhalation route |
| 02/18/2004 | EP1389044A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1216248B1 Triazolopyrimidine derivatives |
| 02/18/2004 | EP1216238B1 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1133477B1 Substituted benzimidazoles and their use as parp inhibitors |
| 02/18/2004 | EP1123314B1 Use of a cytokine-producing lactococcus strain to treat colitis |
| 02/18/2004 | EP1119568B1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 02/18/2004 | EP1104422B1 Phenyl xanthine derivatives |
| 02/18/2004 | EP1032396B1 Sterilization of glucocorticosteroids |
| 02/18/2004 | EP0941110B1 Uses of keratinocyte growth factor-2 |
| 02/18/2004 | EP0863765B1 Pharmaceutical compositions of cyclosporine with a polyethoxylated saturated hydroxy-fatty acid |
| 02/18/2004 | EP0851857B1 Inhibitors of tumor necrosis factor alpha |
| 02/18/2004 | EP0759922B1 New antagonist compounds |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |